Press Releases

Date	Summary	View
Toggle SummaryDec 06, 2018	RedHill Biopharma Announces Pricing of $20 Million Underwritten Offering TEL-AVIV, Israel and RALEIGH, N.C. , Dec. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced the ...	View HTML PDF Version
Toggle SummaryDec 04, 2018	RedHill Biopharma Announces Proposed Public Offering of its American Depositary Shares TEL-AVIV, Israel and RALEIGH, N.C. , Dec. 04, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...	View HTML PDF Version
Toggle SummaryDec 03, 2018	RedHill Biopharma Announces Positive Top-Line Results from Confirmatory Phase 3 Study with TALICIA® for H. pylori Infection The ERADICATE Hp2 confirmatory Phase 3 study successfully met its primary endpoint of H. pylori eradication (84% vs. 58%) with high degree of statistical significance (p ...	View HTML PDF Version
Toggle SummaryNov 29, 2018	RedHill Biopharma to Present at BMO 2018 Prescriptions for Success Healthcare Conference TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 29, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...	View HTML PDF Version
Toggle SummaryNov 14, 2018	RedHill Biopharma Announces Presentation on YELIVA® (opaganib) for Multiple Myeloma at EORTC-NCI-AACR Symposium TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases and cancer, today ...	View HTML PDF Version
Toggle SummaryNov 13, 2018	RedHill Biopharma Reports Third Quarter 2018 Financial Results and Business Highlights Key Highlights: Top-line results from the confirmatory Phase III study with TALICIA ® for H. pylori infection are on track to be announced by year-end 2018, with potential NDA filing in early 2019 Positive top-line results from the Phase III study with RHB-104 for Crohn’s disease - the study ...	View HTML PDF Version
Toggle SummaryNov 06, 2018	RedHill Biopharma to Host Third Quarter 2018 Financial Results Conference Call on November 13, 2018 TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...	View HTML PDF Version
Toggle SummaryOct 29, 2018	RedHill Biopharma to Host Analyst and Investor Webcast on TALICIA® for H. pylori infection on October 30, 2018 Top-line results from the ERADICATE Hp2 confirmatory Phase III study expected before year-end 2018 H. pylori bacterial infection affects over 50% of the adult population worldwide and 30-40% of the U.S. population TEL-AVIV, Israel and RALEIGH, N.C. , Oct. ...	View HTML PDF Version
Toggle SummaryOct 25, 2018	RedHill Biopharma to Present at the BIO-Europe 2018 Conference TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 25, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...	View HTML PDF Version
Toggle SummaryOct 24, 2018	RedHill Biopharma Announces Final Patient Assessed in Confirmatory Phase III Study with TALICIA® for H. pylori Infection RedHill will host an Analyst and Investor Webcast on TALICIA ® for H. pylori infection on Tuesday, October 30, 2018 , at 8:30 a.m. EDT Final patient assessed for primary endpoint, with top-line results expected before year-end 2018 If successful, RedHill plans to file a U.S. ...	View HTML PDF Version

Subscribe to press releases